Elena V Rosca

Summary

Publications

  1. ncbi Structure-activity relationship study of collagen-derived anti-angiogenic biomimetic peptides
    Elena V Rosca
    Department of Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA
    Chem Biol Drug Des 80:27-37. 2012
  2. ncbi Collagen IV and CXC chemokine-derived antiangiogenic peptides suppress glioma xenograft growth
    Elena Victoria Rosca
    Department of Biomedical Engineering, Johns Hopkins University, School of Medicine, Baltimore, Maryland, USA
    Anticancer Drugs 23:706-12. 2012
  3. ncbi Development of a biomimetic peptide derived from collagen IV with anti-angiogenic activity in breast cancer
    Elena V Rosca
    Department of Biomedical Engineering School of Medicine, Johns Hopkins University, Baltimore, MD, USA
    Cancer Biol Ther 12:808-17. 2011
  4. ncbi Novel peptide-specific quantitative structure-activity relationship (QSAR) analysis applied to collagen IV peptides with antiangiogenic activity
    Corban G Rivera
    Department of Biomedical Engineering, 613 Traylor Building, Johns Hopkins University, 720 Rutland Avenue, Baltimore, Maryland 21205, United States
    J Med Chem 54:6492-500. 2011
  5. ncbi Small peptides derived from somatotropin domain-containing proteins inhibit blood and lymphatic endothelial cell proliferation, migration, adhesion and tube formation
    Esak Lee
    Department of Chemical and Biomolecular Engineering, School of Engineering, Johns Hopkins University, Baltimore, MD 21218, United States
    Int J Biochem Cell Biol 43:1812-21. 2011
  6. ncbi Synergy between a collagen IV mimetic peptide and a somatotropin-domain derived peptide as angiogenesis and lymphangiogenesis inhibitors
    Jacob E Koskimaki
    Department of Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA
    Angiogenesis 16:159-70. 2013
  7. ncbi Anti-angiogenic peptides for cancer therapeutics
    Elena V Rosca
    Department of Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA
    Curr Pharm Biotechnol 12:1101-16. 2011
  8. ncbi Peptides derived from type IV collagen, CXC chemokines, and thrombospondin-1 domain-containing proteins inhibit neovascularization and suppress tumor growth in MDA-MB-231 breast cancer xenografts
    Jacob E Koskimaki
    Department of Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA
    Neoplasia 11:1285-91. 2009
  9. ncbi Serpin-derived peptides are antiangiogenic and suppress breast tumor xenograft growth
    Jacob E Koskimaki
    Department of Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD, USA
    Transl Oncol 5:92-7. 2012

Collaborators

Detail Information

Publications9

  1. ncbi Structure-activity relationship study of collagen-derived anti-angiogenic biomimetic peptides
    Elena V Rosca
    Department of Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA
    Chem Biol Drug Des 80:27-37. 2012
    ....
  2. ncbi Collagen IV and CXC chemokine-derived antiangiogenic peptides suppress glioma xenograft growth
    Elena Victoria Rosca
    Department of Biomedical Engineering, Johns Hopkins University, School of Medicine, Baltimore, Maryland, USA
    Anticancer Drugs 23:706-12. 2012
    ....
  3. ncbi Development of a biomimetic peptide derived from collagen IV with anti-angiogenic activity in breast cancer
    Elena V Rosca
    Department of Biomedical Engineering School of Medicine, Johns Hopkins University, Baltimore, MD, USA
    Cancer Biol Ther 12:808-17. 2011
    ....
  4. ncbi Novel peptide-specific quantitative structure-activity relationship (QSAR) analysis applied to collagen IV peptides with antiangiogenic activity
    Corban G Rivera
    Department of Biomedical Engineering, 613 Traylor Building, Johns Hopkins University, 720 Rutland Avenue, Baltimore, Maryland 21205, United States
    J Med Chem 54:6492-500. 2011
    ..We found that the models produced quantitatively accurate predictions of activity and provided insight into collagen IV derived peptide structure-activity relationships...
  5. ncbi Small peptides derived from somatotropin domain-containing proteins inhibit blood and lymphatic endothelial cell proliferation, migration, adhesion and tube formation
    Esak Lee
    Department of Chemical and Biomolecular Engineering, School of Engineering, Johns Hopkins University, Baltimore, MD 21218, United States
    Int J Biochem Cell Biol 43:1812-21. 2011
    ....
  6. ncbi Synergy between a collagen IV mimetic peptide and a somatotropin-domain derived peptide as angiogenesis and lymphangiogenesis inhibitors
    Jacob E Koskimaki
    Department of Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA
    Angiogenesis 16:159-70. 2013
    ....
  7. ncbi Anti-angiogenic peptides for cancer therapeutics
    Elena V Rosca
    Department of Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA
    Curr Pharm Biotechnol 12:1101-16. 2011
    ..g., through L-to-D and non-natural amino acid substitutions. We highlight technological advances in peptide discovery and optimization including computational and bioinformatics tools and novel experimental techniques...
  8. ncbi Peptides derived from type IV collagen, CXC chemokines, and thrombospondin-1 domain-containing proteins inhibit neovascularization and suppress tumor growth in MDA-MB-231 breast cancer xenografts
    Jacob E Koskimaki
    Department of Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA
    Neoplasia 11:1285-91. 2009
    ..We have demonstrated significant suppression of tumor growth in vivo and subsequent reductions in microvascular density, indicating the potential of these peptides as therapeutic agents for breast cancer...
  9. ncbi Serpin-derived peptides are antiangiogenic and suppress breast tumor xenograft growth
    Jacob E Koskimaki
    Department of Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD, USA
    Transl Oncol 5:92-7. 2012
    ..We tested the peptide derived from DEAH box helicase protein in a triple-negative MDA-MB-231 breast orthotopic xenograft model in severe combined immunodeficient mice and show significant tumor suppression...